101 completed, 21 unknown, 19 terminated, 7 recruiting. 46 Phase 2, 43 Phase 1, 36 Phase 3, 23 Phase 4, 11 Not applicable.
Follow Imiquimod: new trials by email Literature Review of Imiquimod trials Research Report on Imiquimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Not yet recruiting | German Cancer Research Center | 216 | 2027-02-01 | 2026-10-22 |
| Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients Imiquimod 5% cream, Nivolumab - Vulvar Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Centre Leon Berard | 50 | 2026-09-01 | 2026-09-30 |
| Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma cemiplimab, Topical imiquimod - Cutaneous Basal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Instituto Oncológico Dr Rosell | 18 | 2025-10-22 | 2025-12-01 |
| Topical Imiquimod Treatment of Oral Dysplasia Imiquimod (topical use) - Oral Dysplasia, Leukoplakia Oral | Phase 1 / Phase 2 | Recruiting | University of Southern California | 20 | 2025-10-01 | 2026-03-04 |
| Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia Imiquimod 5% Topical Cream - Sebaceous Hyperplasia | Phase 4 | Completed | University of Michigan | 11 | 2025-03-11 | 2026-08-11 |
| HPV Vaccine, Imiquimod, and Metformin Combination Trial HPV vaccine, Imiquimod, and metformin combination therapy - Cervical Carcinoma, Vaginal Carcinoma | Phase 2 | Recruiting | Baylor College of Medicine | 85 | 2024-08-23 | 2024-11-13 |
| Deep Phenotyping of Cutaneous Lupus Erythematosus IMIQUIMOD cream 50mg/g - Cutaneous Lupus Erythematosus | Not applicable | Unknown | Centre for Human Drug Research, Netherlands | 40 | 2024-06-01 | 2024-05-13 |
| Real-world Evaluation of Diagnostic and Treatment Strategies in Low-Risk Basal Cell Carcinoma Imiquimod Topical - Basal Cell Carcinoma | Unknown | Maastricht University Medical Center | 142 | 2024-04-22 | 2024-05-01 | |
| Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod Imiquimod, Loop Electrosurgical Excision Procedure - HSIL, High-Grade Squamous Intraepithelial Lesions, Vaginal Microbiome | Phase 4 | Recruiting | Barretos Cancer Hospital | 96 | 2024-04-02 | 2025-02-05 |
| CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults Treatment with CD200AR-L - Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma | Phase 1 | Recruiting | OX2 Therapeutics | 24 | 2024-03-15 | 2024-03-12 |
| Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides Imiquimod, Radiation Therapy - Mycosis Fungoides | Early Phase 1 | Recruiting | Northwestern University | 25 | 2023-07-24 | 2026-05-01 |
| A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas Tecentriq 1200 MG in 20 ML Injection, H3K27M peptide vaccine, Imiquimod (5%) - Newly Diagnosed H3-mutated Glioma | Phase 1 | Active not recruiting | German Cancer Research Center | 15 | 2023-02-15 | 2026-09-15 |
| Coadministration of GA2 Sporozoites With Adjuvants GA2, BCG, YF-17D (fractional ID dose) - Malaria,Falciparum | Early Phase 1 | Unknown | Leiden University Medical Center | 45 | 2023-02-03 | 2023-02-10 |
| Gene and Protein Expression Profiles After Treatment of Actinic Keratoses 5Fluorouracil, Imiquimod, Melatonin - Actinic Keratoses | Phase 2 | Unknown | Ismail Gögenur | 48 | 2023-02-01 | 2023-02-23 |
| A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) UGN-301, UGN-201, Gemcitabine - Non-muscle Invasive Bladder Cancer, NMIBC | Phase 1 | Completed | UroGen Pharma Ltd. | 51 | 2022-06-01 | 2026-01-14 |
| Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment Imiquimod, 3x vaginal swab for microbiome analysis, Expectative management - Cervical High Grade Squamous Intraepithelial Lesion, Cervical Intraepithelial Neoplasia Grade 2/3 | Recruiting | Catharina Ziekenhuis Eindhoven | 410 | 2022-06-01 | 2023-09-11 | |
| Neoadjuvant Imiquimod Immunotherapy for Oral Cancer Imiquimod 5% Cream - Oral Squamous Cell Carcinoma | Early Phase 1 | Completed | Medical University of South Carolina | 16 | 2022-04-28 | 2025-01-28 |
| Efficacy of Tazarotene in Treatment of Verruca Plana Tazarotene 0.1% Gel,Top, Imiquimod, Fluorouracil Cream - Warts Flat | Phase 2 | Unknown | Zagazig University | 80 | 2022-04-15 | 2022-05-16 |
| Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial Imiquimod 5% cream, Placebo cream, Fulguration - Anogenital Human Papillomavirus Infection, Condyloma Anal | Phase 3 | Unknown | Medical University Innsbruck | 200 | 2021-11-15 | 2020-09-23 |
| Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream Imiquimod 3.75% Cream - Actinic Keratoses | Phase 4 | Completed | Medical University of Graz | 48 | 2021-04-16 | 2022-01-11 |
Showing 20 of 156. Sign in to see all of them.
Keratosis, Actinic (29) · Uterine Cervical Dysplasia (14) · Carcinoma, Basal Cell (12) · Melanoma (10) · Glioblastoma (7) · Glioma (7) · Breast Neoplasms (5) · Condylomata Acuminata (4) · Influenza, Human (4) · Keratosis (4) · Neoplasm Metastasis (4) · Uterine Cervical Neoplasms (4) · Astrocytoma (3) · Brain Neoplasms (3) · HIV Infections (3)
MEDA Pharma GmbH & Co. KG (9) · Graceway Pharmaceuticals, LLC (7) · The University of Hong Kong (6) · Maastricht University Medical Center (5) · Medical University of Vienna (4) · Medical University of Graz (3) · University Hospital Tuebingen (3) · AIDS Malignancy Consortium (2) · Actavis Inc. (2) · Barretos Cancer Hospital (2) · German Cancer Research Center (2) · Immatics Biotechnologies GmbH (2) · LEO Pharma (2) · Macarena De La Fuente, MD (2) · Masonic Cancer Center, University of Minnesota (2)
United States (76) · Germany (14) · Netherlands (12) · Austria (10) · France (8) · United Kingdom (6) · Brazil (5) · Canada (5) · Australia (4) · Belgium (4) · Hong Kong (4) · China (3) · Italy (3) · Switzerland (3) · Denmark (2)
Ivan FN Hung, MD FRCP (3) · Sylvia Adams, MD (3) · Klara Mosterd, MD, PhD (2) · A.J. Kruse, MD, PhD (1) · Addie N Alkhas, MD (1) · Alan Zhou (1) · Alessandro D Santin, MD (1) · Alexandra Geusau, Prof. Dr. (1) · Ali Dana, MD (1) · Andrea Mayer-Mokler (1) · Andrea R Thurman, MD (1) · Angela Krackhardt, Prof.Dr.med. (1)
PMID 22914404, PMID 21907959, PMID 23489374, PMID 23843155, PMID 24201682, PMID 28173776, PMID 10451482, PMID 10764464, PMID 10796771, PMID 11132125, PMID 11595691, PMID 15863172, PMID 16174242, PMID 16473126, PMID 17034468, PMID 1731281, PMID 17655918, PMID 17919718, PMID 17959735, PMID 18385498, PMID 18407790, PMID 18566444, PMID 18801868, PMID 19419474, PMID 19466962, PMID 19555364, PMID 19586656, PMID 19597914, PMID 19636365, PMID 19640281, PMID 19943823, PMID 20409337, PMID 20556751, PMID 20666194, PMID 20729935, PMID 20938424, PMID 20952254, PMID 21173650, PMID 21288852, PMID 21345402, PMID 21377898, PMID 21530398, PMID 22177579, PMID 22244840, PMID 22742517, PMID 22767669, PMID 22771223, PMID 23042206, PMID 23094124, PMID 23117059
2015 (2), 2016 (2), P50CA098252 (2), U01CA121947 (2), 2004 (1), 2014 (1), 2025 (1), N01CN00031 (1), P30CA023074 (1), R01CA138521 (1), R01CA161891 (1), R01CA174858 (1), R21CA123876 (1), R21CA128232 (1), R21CA252441 (1)